Bevasiranib

Drug Profile

Bevasiranib

Alternative Names: Bevasiranib sodium; Cand 5

Latest Information Update: 05 Nov 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Opko Health
  • Developer OPKO Health
  • Class Eye disorder therapies; Small interfering RNA
  • Mechanism of Action RNA interference; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration

Most Recent Events

  • 07 Mar 2009 Discontinued - Phase-III for Age-related macular degeneration in Canada (Intravitreous)
  • 07 Mar 2009 Discontinued - Phase-III for Age-related macular degeneration in USA (Intravitreous)
  • 08 Dec 2008 OPKO Health completes enrolment in the phase III COBALT trial for Age-related macular degeneration in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top